Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in Blood Advances, a journal of ...
May 5, 2021
0
13
A McMaster stem cell research team has made an important early step in developing a new class of therapeutics for patients with a deadly blood cancer.
Feb 16, 2021
0
10
A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 percent improvement in survival in patients with acute myeloid ...
Dec 23, 2020
0
113
(HealthDay)—A pair of studies shed new light on why a relatively rare blood cancer—acute myeloid leukemia (AML)—is more deadly among Black patients.
Dec 11, 2020
1
2
Self-reported patient race is the most important factor associated with poorer survival in patients with acute myeloid leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology, ...
Dec 9, 2020
0
1
Patients participating in The Leukemia & Lymphoma Society's (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard ...
Oct 27, 2020
0
33
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by ...
Aug 13, 2020
0
5
Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply. A tyrosine ...
Jul 31, 2020
0
72
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by ...
May 28, 2020
0
8
The cardioprotective drug dexrazoxane preserved cardiac function in pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML) without compromising overall patient survival and potentially improving it, according ...
Apr 28, 2020
0
0
